| |
June 12-14, 2023 | San Diego, CA Digital Pharma Engage is an exclusive, invite-only summit for senior marketing executives from top pharma and biotech companies to come together to network, meet with relevant solution providers and discuss cutting-edge trends in the industry. Learn more! 
|
|
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now. 
|
|
| By Eric Sagonowsky Pfizer was among the drugmakers most elevated by the COVID-19 pandemic, and, going forward, the pharma giant has no plans to give up on its current momentum. |
|
|
|
By Gabrielle Masson Eli Lilly’s plate is full this year, CMO says from the sidelines of the J.P. Morgan Healthcare conference, with five potential launches cooking and 10 top priorities. |
By Angus Liu After GSK quickly pulled its accelerated approval for Blenrep after a confirmatory trial failure, FDA commissioner Robert Califf has weighed in on the state of the regulatory pathway. |
By Andrea Park SAN FRANCISCO—"There’s nothing more fun than the chaos of success." Dexcom CEO Kevin Sayer discussed the worldwide launch of the newly FDA-cleared G7 glucose monitor with Fierce Medtech at the J.P. Morgan Healthcare Conference on Tuesday. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now. 
|
|
By Kevin Dunleavy As Takeda prepares to launch its dengue vaccine after a decade in development, there are many more uncertainties than with the launch of a traditional commercial product. Nevertheless, the Japanese drugmaker is expanding its manufacturing capacity for Qdenga in anticipation of strong demand, CEO Christophe Weber said on Monday afternoon at the J.P. Morgan Healthcare Conference. |
By Nick Paul Taylor Pfizer is stepping back from early-stage rare disease R&D. After reviewing its portfolio, the Big Pharma has begun “exploring externalization opportunities for a number of highly innovative, niche programs” as part of a rethink of its approach to orphan indications. |
By Angus Liu While Novo Nordisk, AstraZeneca and Eli Lilly are set to lead their pharma peers with the most top-line growth this year, Merck & Co. and Sanofi are notably absent from the projection despite major expected contributions from their star meds, a new Evaluate report shows. |
By Conor Hale The move follows a string of major medtechs in the past year pushing their internal business units to take flight as separate companies. |
By Fraiser Kansteiner Friday, the U.S. Food and Drug Administration signed off on the accelerated approval of the Eisai and Biogen's antibody lecanemab in Alzheimer's disease, where it will now carry the commercial moniker Leqembi. Meanwhile, the partners are taking a cautious, "phased approach" to the launch, Eisai's U.S. CEO Ivan Cheung said in an interview. |
By James Waldron In a sign of BioNTech’s growing confidence and ambitions, the mRNA leader announced a deal struck directly with the U.K. government to recruit patients for trials of the German biotech’s cancer immunotherapies. |
By Helen Floersh Systematically profiling the way pancreatic cancer cells suppress the immune system led scientists to a treatment that showed long-term, disease-free survival of up to 90% in mouse models. |
By Ben Adams The questions came thick and fast at this year’s J.P. Morgan Healthcare Conference in San Francisco for Pfizer CEO Albert Bourla. Many at first focused on the pharma’s COVID-19 drug and vaccine business, but attention turned, inevitably, to what’s coming next. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the FDA's shifting stance on cancer drug approvals. Plus, we cover the annual JPM week and other top headlines from this week. |
|
|---|
|
|
|
In this paper, we explore how Truveta, a healthcare analytics company, is addressing how to cut through the noise that often comes with real world data and understand what constitutes a real signal requiring deeper evaluation. Download now to learn more. 
|
|
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Whitepaper This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
eBook Download now to learn about the benefits of transitioning from intravenous to subcutaneously administration, the advantages of using prefilled syringes, and explore challenges and solutions for transitioning from vials to prefilled syringes. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
